Risk
Why Battered Biotech May Be Turning Around
This cyclical sector has suffered, post-pandemic, but signs of a recovery are appearing.
Tag: Pfizer
Biotech Blues: Their Stocks Tank as Newly Public Firms Find Trouble
The urge to do an IPO was strong, and for some, much too early. Maybe staying private before maturing is a good idea for companies, especially biotech ones. That’s...
Do Stock Buybacks Really Shrink Capital Spending?
Thanks to soaring corporate cash, capex has improved lately, but share repurchases still overshadow it.
Asset Allocation
Get Ready for a Biotech M&A Comeback
RBC Capital, heartened by some billion-dollar-plus deals, sees a new buyout hunger in Big Pharma.
Europe’s Venture Capital Finally Flowers, Luring Institutional Investors
Why big allocators on this side of the Atlantic, like CalSTRS, CPPIB, and OMERS, are seeding Old World newbie companies.
Market Moves
Ackman Bets on a Pandemic Bond Wipeout—Again
His new bearish investment is similar to the one in March that earned him a $2.6 billion jackpot.
Market Moves
Good Vaccine News Has Immediate Impact on the Stock Market
A quarter of the S&P 500’s rise since May is linked to positive developments on a virus inoculation, UBS says.